@prefix rdf: . @prefix ns1: . @prefix ns2: . ns1:DB00398 rdf:type ns2:Drug ; ns2:description "Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received \"Fast Track\" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway."@en ; ns2:dosage , ; ns2:generalReferences "# FDA label "@en ; ns2:group "investigational"@en , "approved"@en ; ns2:halfLife "25-48 hours"@en ; ns2:indication "Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. "@en ; ns2:manufacturer . @prefix owl: . @prefix ns4: . ns1:DB00398 owl:sameAs ns4:DB00398 . @prefix ns5: . ns1:DB00398 owl:sameAs ns5:DB00398 . @prefix dcterms: . ns1:DB00398 dcterms:title "Sorafenib"@en . @prefix adms: . @prefix ns8: . ns1:DB00398 adms:identifier ns8:D08524 . @prefix ns9: . ns1:DB00398 adms:identifier ns9:Sorafenib , , . @prefix ns10: . ns1:DB00398 adms:identifier ns10:BAX . @prefix ns11: . ns1:DB00398 adms:identifier ns11:PA7000 , . @prefix ns12: . ns1:DB00398 adms:identifier ns12:DB00398 , , , ; ns2:mechanismOfAction "Sorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor. Sorafenib is unique in targeting the Raf/Mek/Erk pathway. By inhibiting these kinases, genetic transcription involving cell proliferation and angiogenesis is inhibited."@en ; ns2:packager ; ns2:patent , , ; ns2:routeOfElimination "Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose excreted in feces, and 19% of the dose excreted in urine as glucuronidated metabolites."@en ; ns2:synonym "N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea"@en , "Sorafenibum"@en , "4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide"@en ; ns2:toxicity "The highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals."@en . @prefix ns13: . ns1:DB00398 ns13:hasAHFSCode ; ns2:proteinBinding "99.5% bound to plasma proteins. "@en ; ns2:salt " "@en ; ns2:synthesisReference "Ales Gavenda, Alexandr Jegorov, Pierluigi Rossetto, Peter Lindsay MacDonald, Augusto Canavesi, \"POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF.\" U.S. Patent US20090192200, issued July 30, 2009."@en . @prefix ns14: . @prefix ns15: . ns1:DB00398 ns14:hasConcept ns15:M0446095 . @prefix foaf: . ns1:DB00398 foaf:page , ; ns2:IUPAC-Name ; ns2:InChI ; ns2:Molecular-Formula ; ns2:Molecular-Weight ; ns2:Monoisotopic-Weight ; ns2:SMILES ; ns2:Water-Solubility , ; ns2:logP , , ; ns2:logS . @prefix ns17: . ns1:DB00398 ns13:hasATCCode ns17:L01XE05 ; ns2:H-Bond-Acceptor-Count ; ns2:H-Bond-Donor-Count ; ns2:InChIKey ; ns2:Polar-Surface-Area--PSA- ; ns2:Polarizability ; ns2:Refractivity ; ns2:Rotatable-Bond-Count ; ns2:absorption "The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. Sorafenib reached peak plasma levels in 3 hours following oral administration. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state."@en ; ns2:affectedOrganism "Humans and other mammals"@en ; ns2:casRegistryNumber "284461-73-0"@en ; ns2:category " "@en ; ns2:containedIn ; ns2:Bioavailability ; ns2:Ghose-Filter ; ns2:MDDR-Like-Rule ; ns2:Number-of-Rings ; ns2:Physiological-Charge ; ns2:Rule-of-Five ; ns2:Traditional-IUPAC-Name ; ns2:pKa--strongest-acidic- ; ns2:pKa--strongest-basic- .